Trials / Conditions / High Grade Ovarian Serous Adenocarcinoma

High Grade Ovarian Serous Adenocarcinoma

15 registered clinical trials studyying High Grade Ovarian Serous Adenocarcinoma — 6 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	High Definition Profiling of Ovarian Cancer Ascites NCT06553742	European Institute of Oncology	—
Recruiting	This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatmen NCT06451497	Zumutor Biologics Inc.	Phase 1
Recruiting	Alternative Dosing Of Niraparib To Decrease Dose Interruption In First Line Maintenance Treatment For Ovarian NCT05961124	Sunnybrook Health Sciences Centre	Phase 2
Recruiting	Modi-1 Moditope in Breast, Head and Neck, Ovarian, or Renal Cancer NCT05329532	Scancell Ltd	Phase 1 / Phase 2
Active Not Recruiting	Pembrolizumab and Lenvatinib for the Treatment of Serous Ovarian Cancer Patients NCT05114421	M.D. Anderson Cancer Center	Phase 2
Terminated	Olaparib and Entinostat in Patients With Recurrent, Platinum-Refractory, Resistant Ovarian, Primary Peritoneal NCT03924245	Vanderbilt-Ingram Cancer Center	Phase 1
Recruiting	Developing a Test of Uterine Lavage for the Detection of Ovarian Cancer NCT04794322	Massachusetts General Hospital	—
Active Not Recruiting	Olaparib in Treating Patients With Newly Diagnosed BRCA-Mutant Ovarian, Primary Peritoneal, or Fallopian Cance NCT03943173	M.D. Anderson Cancer Center	EARLY_Phase 1
Active Not Recruiting	Niraparib and Copanlisib in Treating Patients With Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fall NCT03586661	M.D. Anderson Cancer Center	Phase 1
Active Not Recruiting	Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer NCT03907852	TCR2 Therapeutics	Phase 1 / Phase 2
Terminated	Lavage of the Uterine Cavity for Diagnosis of Ovarian Cancer NCT03606486	University of Washington	N/A
Withdrawn	Birinapant and Carboplatin in Treating Patients and Targeting Recurrent High Grade Ovarian, Fallopian Tube, or NCT02756130	Jonsson Comprehensive Cancer Center	Phase 1 / Phase 2
Completed	Talazoparib in Determining Genetic Effects on Disease Response in Patients With Advanced Ovarian, Fallopian Tu NCT02316834	M.D. Anderson Cancer Center	EARLY_Phase 1
Active Not Recruiting	mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian NCT02208375	M.D. Anderson Cancer Center	Phase 1
Recruiting	Multi-layer Data to Improve Diagnosis, Predict Therapy Resistance and Suggest Targeted Therapies in HGSOC NCT04846933	Turku University Hospital	N/A